Managed Access Program for Momelotinib in Myelofibrosis

Safety Study Evaluating Twice-Daily Administration of Momelotinib in Primary Myelofibrosis or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis

NCT01423058 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Momelotinib During and After HCT in Myelofibrosis

NCT07104799 ·Status: RECRUITING ·Phase: PHASE1

Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET)

NCT00935987 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Myelofibrosis and Essential Thrombocythemia Observational Study (MOST)

NCT02953704 ·Status: COMPLETED

Momelotinib Effectiveness in Myelofibrosis

NCT07249606 ·Status: NOT_YET_RECRUITING

A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis

NCT04176198 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

A Phase II Non-Controlled, Open-Label, Efficacy, Safety, Pharmacokinetic, and Pharmacodynamic Study of Pacritinib in Myelofibrosis

NCT02584777 ·Status: WITHDRAWN ·Phase: PHASE2

A Clinical Trial of Flonoltinib Maleate for Intermediate or High-Risk Myelofibrosis

NCT07317700 ·Status: RECRUITING ·Phase: PHASE3

Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia

NCT05320198 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

Phase I/II Trial to Investigate BI 836858 in Myelodysplastic Syndromes

NCT02240706 ·Status: TERMINATED ·Phase: PHASE2

Extension Study Evaluating the Long Term Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET)

NCT01236638 ·Status: COMPLETED ·Phase: PHASE2

A Study of Ruxolitinib in Combination With Abemaciclib for the Treatment of Myelofibrosis

NCT05714072 ·Status: RECRUITING ·Phase: PHASE1

Pacritinib Versus Best Available Therapy to Treat Myelofibrosis

NCT01773187 ·Status: TERMINATED ·Phase: PHASE3

Phase III Study Investigating the Efficacy and Safety of Ruxolitinib in Early Myelofibrosis Patients With High Molecular Risk Mutations.

NCT02598297 ·Status: TERMINATED ·Phase: PHASE3

Erlotinib in Higher Risk Myelodysplastic Syndrome

NCT01085838 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

A Study of LNK01002 in Patients With Primary or Secondary Myelofibrosis,Polycythemia Vera or Acute Myeloid Leukemia

NCT04896112 ·Status: WITHDRAWN ·Phase: PHASE1

Study of Sotatercept for the Treatment of Anemia in low-or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) or Non-proliferative Chronic Myelomonocytic Leukemia (CMML)

NCT01736683 ·Status: COMPLETED ·Phase: PHASE2

Study of SB939 in Subjects With Myelofibrosis

NCT01200498 ·Status: COMPLETED ·Phase: PHASE2

A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia

NCT05980806 ·Status: RECRUITING ·Phase: PHASE2

A Study of Elritercept Alone or Together With Ruxolitinib in Adults With Myelofibrosis

NCT05037760 ·Status: RECRUITING ·Phase: PHASE2

A Study to Evaluate Safety and Efficacy of Panobinostat in Participants With Primary Myelofibrosis

NCT00931762 ·Status: TERMINATED ·Phase: PHASE2

Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib

NCT05280509 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

A Safety and Tolerability Study of Jaktinib

NCT05279001 ·Status: RECRUITING ·Phase: PHASE1

Phase 2 Study of SAR302503 in Patients With Myelofibrosis

NCT01420770 ·Status: COMPLETED ·Phase: PHASE2

INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders

NCT04455841 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2